The Mantle Cell Lymphoma Research Initiative II – Synergistic Team Award funded by the Leukemia and Lymphoma Society (LLS) supports targeted research to better understand disease mechanisms, develop more efficacious treatments and improve the outcome for MCL patients. This program is primarily focused on relapsed disease. However, novel work focused on early disease intervention or improved risk stratification is of interest. LLS calls for the submission of creative proposals with the potential for high impact in MCL. Applications should address both transformative issues in MCL biology and promising new directions in MCL therapy.
The Synergistic Team Award (STA) will support substantial, collaborative projects addressing a significant obstacle in understanding and treating MCL. Applications are open to researchers worldwide at reputable academic research institutions. Applicants may apply for up to 3 million USD in funding over 4 years, including 10% indirect costs.
Letters of intent are due by December 5, 2022. Full applications close on February 24, 2023.
